Abstract
Objectives: To identify the factors associated with flares after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and to determine whether belimumab (BLM) influences this risk. Methods: Using the ANSWER-SLE cohort, this retrospective, multicentre study enrolled 388 patients with a GC reduction from ≤5 mg/day. The primary outcome was the time to an overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase of ≥3 or a GC escalation). Multivariable Cox models identified factors associated with an overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between BLM and flare risk. Results: During a 1-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). A higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03–1.17), Systemic Lupus International Collaborating Clinics Damage Index (SDI) (HR 1.11, 95% CI 1.01–1.22), and GC dose reduction (HR 1.40, 95% CI 1.15–1.70) were associated with an increased overall flare risk. GC reductions of >1 mg were associated with flare (HR 2.53, 95% CI 1.54–4.15). In the weighted analyses, BLM was not associated with an overall flare (HR 0.83, 95% CI 0.51–1.34). Conclusions: In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas BLM was not associated with a reduced flare risk.

This publication has 19 references indexed in Scilit: